Brief: Detalimogene Demonstrates 71% Complete Response Rate At Any Time In Preliminary Analysis Of Legend Pivotal Cohort

enGene Therapeutics

26/09/2024 11:31

Sept 26 (Reuters) - enGene Holdings Inc  ENGN.O :
    * DETALIMOGENE DEMONSTRATES 71% COMPLETE RESPONSE RATE AT
ANY TIME
IN PRELIMINARY ANALYSIS OF LEGEND PIVOTAL COHORT
    * ENGENE HOLDINGS INC - DATA FROM PIVOTAL COHORT DEMONSTRATE
COMPELLING CLINICAL ACTIVITY, CONSISTENT WITH PHASE 1 RESULTS
    * ENGENE HOLDINGS INC - FAVORABLE TOLERABILITY PROFILE WITH
NO
DRUG-RELATED DISCONTINUATIONS

Source text for Eikon:  ID:nBw9y6K9Sa 
Further company coverage:  ENGN.O 

 ((Reuters.Briefs@thomsonreuters.com;))